Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn — Stella

Recruiting

Back to Hemolytic Disease of Newborn trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

Saudi Arabia

Madinah maternity and children's hospital, Madinah

Key details

Sponsor

Ministry of Health, Saudi Arabia

Enrollment target

~84 participants

Started

October 2019

Primary completion

October 2026

Age range

1 Hour – 14 Days

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov